Exercise of the over-allotment option in the IPO of Devyser Diagnostics AB (publ)’s shares and end of the stabilisation period
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASEStockholm, 7 January, 2022 Carnegie Investment Bank AB (publ) (“Carnegie”) exercises the over-allotment option regarding 610,886 shares in Devyser Diagnostics AB (publ) (“Devyser” or the “Company”). The stabilisation period has now ended and no further